Phase 2 Breast Cancer Trial, Recruiting NCT06806930 Sponsor: George Washington University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06806930
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand what the study involves and all important details about it
  • People who are able to sign and provide written consent following the required guidelines
  • People who have a confirmed diagnosis of invasive breast cancer, proven through laboratory testing of tissue or cell samples
  • People with breast cancer at clinical stage 1, 2, or 3
  • People whose cancer is considered suitable for surgical removal
  • People whose breast cancer tumour tests show estrogen receptor positive results in more than 10% of cells, as documented by a laboratory or medical record
  • People whose breast cancer tests as HER2 negative or HER2 low on their most recent tumour biopsy, as documented by a laboratory or medical record — and, if HER2 low, people who are not considered candidates for HER2-targeted treatment (confirm with trial site)
  • People who are able to swallow and take oral (by mouth) medication
  • People who are willing and able to attend scheduled visits, follow the treatment plan, and stay in contact with the research team
  • People aged 21 years or older

Who may not be able to join:

  • People who are unable to comply with taking neoadjuvant endocrine therapy (NET), which is hormone-based treatment given before surgery (confirm with trial site)
  • People who are unable to follow the study procedures as required

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 202-741-2277

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
George Washington University
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Response to neoadjuvant endocrine therapy (NET)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov